Sitagliptin/Metformin hydrochloride Teva 50 mg/1000 mg apvalkotās tabletes Lettland - Lettisch - Zāļu valsts aģentūra

sitagliptin/metformin hydrochloride teva 50 mg/1000 mg apvalkotās tabletes

teva gmbh, germany - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg

Sitagliptin/Metformin Grindeks 50 mg/850 mg apvalkotās tabletes Lettland - Lettisch - Zāļu valsts aģentūra

sitagliptin/metformin grindeks 50 mg/850 mg apvalkotās tabletes

grindeks, as, latvia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Sitagliptin/Metformin Grindeks 50 mg/1000 mg apvalkotās tabletes Lettland - Lettisch - Zāļu valsts aģentūra

sitagliptin/metformin grindeks 50 mg/1000 mg apvalkotās tabletes

grindeks, as, latvia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg

Segluromet Europäische Union - Lettisch - EMA (European Medicines Agency)

segluromet

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Vildagliptin / Metformin hydrochloride Accord Europäische Union - Lettisch - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - cukura diabēts, 2. tips - cukura diabēts - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Tixulda 50 mg/500 mg modificētās darbības tabletes Lettland - Lettisch - Zāļu valsts aģentūra

tixulda 50 mg/500 mg modificētās darbības tabletes

adamed pharma s.a., poland - sitagliptinum, metformini hydrochloridum - modificētās darbības tablete - 50 mg/500 mg

Tixulda 50 mg/1000 mg modificētās darbības tabletes Lettland - Lettisch - Zāļu valsts aģentūra

tixulda 50 mg/1000 mg modificētās darbības tabletes

adamed pharma s.a., poland - sitagliptinum, metformini hydrochloridum - modificētās darbības tablete - 50 mg/1000 mg

Tixulda 100 mg/1000 mg modificētās darbības tabletes Lettland - Lettisch - Zāļu valsts aģentūra

tixulda 100 mg/1000 mg modificētās darbības tabletes

adamed pharma s.a., poland - sitagliptinum, metformini hydrochloridum - modificētās darbības tablete - 100 mg/1000 mg

Jansitin Duo 50 mg/850 mg apvalkotās tabletes Lettland - Lettisch - Zāļu valsts aģentūra

jansitin duo 50 mg/850 mg apvalkotās tabletes

g.l. pharma gmbh, austria - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Jansitin Duo 50 mg/1000 mg apvalkotās tabletes Lettland - Lettisch - Zāļu valsts aģentūra

jansitin duo 50 mg/1000 mg apvalkotās tabletes

g.l. pharma gmbh, austria - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg